Loading...

Bionomics Limited

BNO.AXASX
Healthcare
Biotechnology
A$0.009
A$-0.00(-10.00%)

Bionomics Limited (BNO.AX) Company Profile & Overview

Explore Bionomics Limited’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Bionomics Limited (BNO.AX) Company Profile & Overview

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.

SectorHealthcare
IndustryBiotechnology
CEOSpyridon Papapetropoulos

Contact Information

61 8 8150 7400
200 Greenhill Road, Eastwood, SA, 5063

Company Facts

140 Employees
IPO DateDec 20, 1999
CountryAU

Frequently Asked Questions

;